| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6182342 | Fertility and Sterility | 2017 | 8 Pages |
Abstract
Hormone treatment with GnRH agonist and/or aromatase inhibition may be a therapeutic option to reduce tumor burden in unresectable BML disease or for those patients who wish to avoid surgical intervention. RECIST 1.1 guidelines, while traditionally used to evaluate tumor response to cancer therapeutics, may be useful in evaluating BML tumor burden response to hormone therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Erin I. M.D., Rebecca J. M.D., Alan H. M.D., Alicia M.D., John M.D., Aradhana M. M.D.,